BRIDGENE BIOSCIENCES, INC.

Biotech · Private

Small-molecule covalent FLT3 inhibitor (BGS2456) for acute myeloid leukemia

Grants
$467K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
22
3 granted · 19 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A Novel Chemical Proteomics Platform to Expand Druggable Space$168,331
Federal grantDepartment of Health and Human Services · Phase I · Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia$298,928
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2246CELLF-BIO LLC——
2247NOUR HEART, INC.——
2248NAPROGENIX, INC.——
2249BRIDGENE BIOSCIENCES, INC.——
2250OpalGenix, Inc.——
2251ProDa BioTech L.L.C.——
2252AUMENTA BIOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 3 granted of 22

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.